Immunonkologie bei Kopf-Hals-Tumoren

Die Immuntherapie mit Immuno-Checkpoint-Inhibitoren hat bei Kopf-Hals-Tumoren einen Durchbruch erzielt und wird bald auch die Hals-Nasen-Ohren-ärztliche Praxis erreichen. In der vorliegenden Übersichtsarbeit soll ausführlich auf die Hintergründe und die Definitionen der Therapieabschnitte (Erstlinie, Zweitlinie, Marker usw.) eingegangen werden. Darüber hinaus soll das Basisrüstzeug zum Verständnis dieser neuen Therapieoption geliefert werden.

Abstract

In the near future, immunotherapy with checkpoint inhibitors will not only reach the relevant ENT clinics, but also the oncologically integrated ENT practice, since more and more patients under long-term therapy (currently up to 2 years) also have to be seen during clinical follow-up in the specialist practice. In this respect, we also consider as necessary that the basics of immuno-oncology in head and neck tumors are already taught as part of the ENT specialist training. In this review article, the background and the definitions of the therapy sections (first, second line treatment, marker, etc.) should be discussed in detail and the basic tools for understanding this new therapy option should be provided. Since 2017, we have been experiencing a high level of approval dynamics for checkpoint inhibitors in Germany, which is to be assessed as an expression of a new effective principle of action and, after surgery, radiation and chemotherapy, is establishing a fourth strong pillar in the multimodal spectrum against head and neck tumors. Right from the start, the checkpoint inhibitors in the first phase 1b, 2 and 2b studies achieved overall response rates of 16–22 % with overall survival rates of 6–8 months in seriously ill patients with HNSCC who already had a first- and/or even second-line therapy. Nivolumab and Pembrolizumab are currently approved in Germany for the first and second line therapy of relapsed/metastatic squamous cell carcinoma of the head and neck region (HNSCC), Cemiplimab for recurrent/metastatic cutaneous squamous cell carcinoma and Avelumab for metastatic recurrent Merkel-cell carcinoma. The synopsis article about immune checkpoint inhibitors is intended to convey the basic understanding of the principle of action, the indication, toxicity management and the further development within trials in head and neck oncology.

Schlüsselwörter

Kopf-Hals-Tumoren - Immuno-Checkpoint-Inhibitoren - PD-L1-Inhibition - CPS - TPS

Key words

head and neck carcinoma - immuno checkpoint inhibitors - PD-L1-inhibition - CPS - TPS

• Literatur

• 1 Ferris RL, Blumenschein Jr G, Fayette J. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016; 375 (19) 1856-1867
• 2 Vermorken JB, Mesia R, Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359 (11) 1116-1127
• 3 Burtness B, Harrington KJ, Greil R. et al. KEYNOTE-048 investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019; 394: 1915-1928
• 4 Chen DS, Mellmann I. Oncology meets immunology: the cancer-immune cycle. Immunity 2013; 39: 1-13
• 5 Qureshi OS, Zheng Y, Nakamura K. et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011; 332: 600-603
• 6 Cohen EEW, Bell RB, Bifulco CB. et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer 2019; 7 (01) 184
• 7 Ferris RL, Blumenschein Jr G, Fayette J. et al. Nivolumab vs investigatorʼs choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 2018; 81: 45-51
• 8 Cohen EEW, Soulières D, Le Tourneau C. et al. KEYNOTE-040 investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019; 393: 156-167
• 9 Siu LL, Even C, Mesía R. et al. Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial. JAMA Oncol 2019; 5 (02) 195-203
• 10 Leduc C, Adam J, Louvet E. et al. TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. ESMO Open 2018; 3 (01) e000257
• 11 Chen DS, Mellmann I. Elements of cancer immunity and the cancer-immune set point. Nature 2017; 541: 321-330
• 12 Macfarlane S, Steed H, Macfarlane GT. Intestinal bacteria and inflammatory bowel disease. Crit Rev Clin Lab Sci 2009; 46: 25-54
• 13 Sivan A, Corrales L, Hubert N. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015; 350: 1084-1089
• 14 Brown K, DeCoffe D, Molcan E. et al. Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Nutrients 2012; 4: 1095-1119
• 15 Harmsen H, Wildeboer-Veloo A, Raangs GC. et al. Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. J Pediatr Gastroenterol Nutr 2000; 30: 61-67
• 16 Fallani M, Young D, Scott J. et al. Intestinal microbiota of 6-week-old infants across Europe: geographic influence beyond delivery mode, breast-feeding, and antibiotics. J Pediatr Gastroenterol Nutr 2010; 51: 77-84
• 17 Koecher KJ, Thomas W, Slavin JL. Healthy subjects experience bowel changes on enteral diets; addition of a fiber blend attenuates stool weight and gut bacteria decreases without changes in gas. J Parenter Enter Nutr 2013; 25: 132-138
• 18 Vaughan EE, Heilig H, Ben-Amor K. et al. Diversity, vitality and activities of intestinal lactic acid bacteria and bifidobacteria assessed by molecular approaches. FEMS Microbiol Rev 2005; 29: 477-490
• 19 Gopalakrishnan V, Spencer CN, Nezi L. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018; 359: 97-103
• 20 Kasper S, Hussain T, Virchow I. et al. Immunonkologie von Kopf-Hals-Tumoren. HNO 2019; 67: 221-235
• 21 Bristol-Myers Squibb Pharma EEIG (BMS). Fachinformation Opdivo, 11/2020. Im Internet (Stand: 25.01.2021): https://www.bms.com/assets/bms/austria/documents/2020-11-20%20OPDIVO-H-3985-II-080-FI-de-clean.pdf
• 22 MSD. Fachinformation Keytruda, 11/2020. Im Internet (Stand: 25.01.2021): https://www.msd.de/fileadmin/files/fachinformationen/keytruda_loesung.pdf
• 23 Merck. Fachinformation Bavencio, 07/2017. Im Internet (Stand: 25.01.2021): https://www.merckgroup.com/at-de/expertise/fachinformationen/bavencio-avelumab-20mgml-konzentrat-infusionsloesung-gesundheitsberufen.pdf
• 24 Gillison ML, Blumenschein Jr G, Fayette J. et al. Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): outcomes in first-line (1L) R/m patients and updated safety and efficacy. J Clin Oncol 2017; 35: abstr 6019
• 25 Dietz A, Welslau M, Hahn D. et al. HANNA: Real-world outcomes from an observational study with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in Germany. J Clin Oncol 2020; 38 (Suppl. 15) 6532
• 26 Greil R, Rischin D, Harrington K. et al Long-term outcomes from KEYNOTE-048: Pembrolizumab alone or with chemotherapy versus EXTREME as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma. Mini oral Nr. 915, presented at ESMO 2020
• 27 Guigay J, Tahara M, Licitra L. et al. The evolving role of taxanes in combination with cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: evidence, advantages, and future directions. Front Oncol 2019; 9: 668
• 28 Kaufman HL, Russell JS, Hamid O. et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer 2018; 6 (01) 7
• 29 Cowey CL, Mahnke L, Espirito J. et al. Real-world outcomes of patients with metastatic Merkel cell caricnoma treated with chemotherapy in the USA. Future Oncol 2017; 13 (19) 1699-1710
• 30 Migden MR, Rischin D, Schmults CD. et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 2018; 379 (04) 341-351
• 31 Pickering CR, Zhou JH, Lee JJ. et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res 2014; 20 (14) 3842-3848
• 32 Larkin J, Chiarion-Sileni V, Gonzalez R. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34
• 33 Naidoo J, Page DB, Li BT. et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26 (12) 2375-2391
• 34 Hanna GJ, Adkins DR, Zolkind P. et al. Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma. Oral Oncol 2017; 73: 65-69
• 35 Zuur L, Vos JL, Elbers JB. et al. LBA40 – Neoadjuvant nivolumab and nivolumab plus ipilimumab induce (near-) complete responses in patients with head and neck squamous cell carcinoma: the IMCISION trial. Ann Oncol 2020; 31 (Suppl. 04) S1142-S1215
• 36 Cohen EE, Ferris RL, Psyrri A. et al. 910O – Primary results of the phase III JAVELIN head & neck 100 trial: avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Ann Oncol 2020; 31 (Suppl. 04) S599-S628